AstraZeneca
AZNCF | OTC
$189.90
-$2.60 (-1.35%)
At close: Mar 13, 2026, 9:30 AM ET
Fiscal Quarter Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q4 2025 Dec 30, 2025 | Q3 2025 Sep 29, 2025 | Q2 2025 Jun 29, 2025 | Q1 2025 Mar 29, 2025 | Q4 2024 Dec 30, 2024 | Q3 2024 Sep 29, 2024 | Q2 2024 Jun 29, 2024 | Q1 2024 Mar 30, 2024 | Q4 2023 Dec 30, 2023 | Q3 2023 Sep 29, 2023 | Q2 2023 Jun 29, 2023 | Q1 2023 Mar 30, 2023 | Q4 2022 Dec 30, 2022 | Q3 2022 Sep 29, 2022 | Q2 2022 Jun 29, 2022 | Q1 2022 Mar 30, 2022 | Q4 2021 Dec 30, 2021 | Q3 2021 Sep 29, 2021 | Q2 2021 Jun 29, 2021 | Q1 2021 Mar 30, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 15.29B | 15.29B | 15.5B | 15.19B | 14.84B | 13.96B | 14.54B | 13.96B | 12.98B | 12.55B | 12.25B | 11.05B | 11.55B | 11.07B | 11.74B | 10.34B | 10.42B | 11.14B | 12.13B | 9.67B | 8.12B | 8.42B |
Cost of Revenue | 4.04B | 2.68B | 3.12B | 2.86B | 3.68B | 3.29B | 4.69B | 4.04B | 3.15B | 3.11B | 3.36B | 2.97B | 2.98B | 3.1B | 4.12B | 3.73B | 3.9B | 4.39B | 5.84B | 4.74B | 2.55B | 2.31B |
Gross Profit | 11.25B | 12.61B | 12.39B | 12.33B | 11.16B | 10.67B | 9.85B | 9.93B | 9.82B | 9.44B | 8.89B | 8.08B | 8.57B | 7.97B | 7.62B | 6.61B | 6.53B | 6.75B | 6.29B | 4.93B | 5.57B | 6.11B |
Operating Income | 3.09B | 4.25B | 2.98B | 3.58B | 3.51B | 3.78B | 1.99B | 2.87B | 2.85B | 3.21B | 1.31B | 1.93B | 1.82B | 2.38B | 1.27B | 1.22B | 639.67M | 836.22M | 403.35M | -98.04M | 1.06B | 1.85B |
Interest Income | 79.52M | 73M | 135M | 85M | 69.82M | 86.29M | 62.48M | 188.39M | 100.31M | 109.88M | 110.04M | 97.08M | 64.74M | 79.35M | 47.15M | 14.12M | 17.42M | 16.63M | 1M | 14.71M | 6.92M | 20.04M |
Pretax Income | 2.78B | 3.91B | 2.63B | 3.24B | 3.21B | 3.49B | 1.63B | 1.88B | 2.4B | 2.77B | 913.91M | 1.59B | 2.11B | 2.3B | 815.24M | 867.69M | 239.03M | 540.85M | -636.56M | -1.96B | 754.81M | 1.61B |
Net Income | 2.49B | 3.08B | 2.33B | 2.53B | 2.52B | 3B | 1.46B | 1.47B | 1.93B | 2.16B | 978.1M | 1.32B | 1.84B | 1.83B | 944.12M | 1.54B | 348.39M | 377.52M | -347.3M | -1.62B | 543.39M | 1.56B |
Selling & General & Admin | 4.51B | 5.06B | 5.65B | 5.12B | 4.1B | 3.72B | 4.37B | 3.9B | 4.09B | 3.56B | 4.62B | 3.76B | 4.15B | 3.25B | 3.7B | 3.16B | 3.53B | 3.76B | 3.47B | 2.92B | 2.74B | 2.62B |
Research & Development | 3.64B | 3.49B | 3.86B | 3.66B | 3.55B | 3.17B | 3.49B | 3.16B | 2.89B | 2.67B | 2.97B | 2.39B | 2.6B | 2.34B | 2.65B | 2.22B | 2.36B | 2.15B | 2.42B | 2.11B | 1.78B | 1.64B |
Other Expenses | n/a | -189M | -100M | -37M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | 1M |
Operating Expenses | 8.15B | 8.36B | 9.41B | 8.75B | 7.65B | 6.89B | 7.86B | 7.06B | 6.97B | 6.23B | 7.59B | 6.15B | 6.75B | 5.59B | 6.35B | 5.38B | 5.89B | 5.91B | 5.89B | 5.03B | 4.52B | 4.26B |
Interest Expense | 432.37M | 393M | 484M | 434M | 450.73M | 358.53M | 418.81M | 470.47M | 444.39M | 408.82M | 453.39M | 376.77M | 435.98M | 371.32M | 377.23M | 319.03M | 300.97M | 328.62M | 336.29M | 328.42M | 322.08M | 303.59M |
Selling & Marketing Expenses | n/a | 141M | 153M | 148M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 12.2B | 11.04B | 12.53B | 11.61B | 11.34B | 10.18B | 12.55B | 11.1B | 10.13B | 9.34B | 10.94B | 9.12B | 9.73B | 8.69B | 10.47B | 9.11B | 9.78B | 10.3B | 11.73B | 9.77B | 7.07B | 6.57B |
Income Tax Expense | 289.24M | 833M | 300M | 709M | 697.15M | 494.14M | 162.06M | 406.64M | 470.47M | 613.72M | -63.17M | 263.36M | 271.1M | 465.92M | -129.93M | -677.59M | -109.35M | 161.38M | -290.25M | -343.13M | 211.43M | 46.09M |
Shares Outstanding (Basic) | 1.55B | 1.55B | 1.55B | 1.56B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.55B | 1.5B | 1.31B | 1.31B |
Shares Outstanding (Diluted) | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.56B | 1.55B | 1.5B | 1.32B | 1.32B |
EPS (Basic) | 1.60 | 1.99 | 1.50 | 1.62 | 1.62 | 1.93 | 0.94 | 0.95 | 1.25 | 1.39 | 0.63 | 0.85 | 1.19 | 1.18 | 0.61 | 1 | 0.22 | 0.24 | -0.22 | -1.08 | 0.41 | 1.19 |
EPS (Diluted) | 1.60 | 1.97 | 1.49 | 1.62 | 1.61 | 1.92 | 0.94 | 0.94 | 1.24 | 1.38 | 0.63 | 0.85 | 1.18 | 1.18 | 0.61 | 0.99 | 0.22 | 0.24 | -0.22 | -1.08 | 0.41 | 1.19 |
EBITDA | 5.01B | 5.67B | 4.62B | 5.14B | 5.1B | 5.18B | 4.33B | 4.23B | 4.14B | 4.44B | 2.72B | 3.21B | 3.84B | 4.2B | 2.74B | 2.44B | 1.85B | 2.16B | 1.9B | 1.11B | 1.86B | 2.72B |
EBIT | 3.09B | 4.31B | 3.11B | 3.59B | 3.67B | 3.86B | 2.05B | 2.36B | 2.85B | 3.19B | 1.37B | 1.98B | 2.55B | 2.67B | 1.19B | 1.19B | 539.03M | 875.34M | -291.25M | -1.63B | 1.12B | 1.92B |
Depreciation & Amortization | 1.92B | 1.37B | 1.51B | 1.55B | 1.43B | 1.32B | 2.28B | 1.87B | 1.28B | 1.24B | 1.35B | 1.23B | 1.29B | 1.53B | 1.55B | 1.26B | 1.31B | 1.28B | 2.19B | 2.73B | 743.95M | 798.55M |
Add to Watchlist
Select watchlists to add or remove AZNCF